Weekly vascular bulletin — September 7, 2026
Revised edition of the bulletin for the week of August 31 to September 7. A slow week for clinical evidence: ESC 2026 brought no peripheral vascular trials and CIRSE is still ongoing with no results yet. Regulatory and industry news dominate; 8 items, figures verified against the source.
Priority areas
1) Medicare approves NTAP for the Spur recoverable stent (infrapopliteal) [Regulatory/Industry]
Up to US$2,596.75 per case starting October 1, 2026, for a maximum of two years. Basis: DEEPER REVEAL (130 patients, 49 centers, single arm). At 12 months, in vessels of 2.5 mm or more measured by a core lab: primary patency 78% and freedom from revascularization 83.1%; complete wound healing 84.3% in the paired analysis of patients with wounds. These are not figures for all 130 patients; the manufacturer does not report denominators. Why it matters: reimbursement, not new evidence; no comparator; manufacturer data.
https://vascularnews.com/cms-approves-new-technology-add-on-payment-for-reflow-medicals-spur-system/
https://www.reflowmedical.com/cms-approves-new-technology-add-on-payment-for-reflow-medicals-spur-peripheral-retrievable-stent-system/
https://vascularnews.com/reflow-medical-announces-12-month-results-from-deeper-reveal-trial/
https://www.businesswire.com/news/home/20260413367126/en/Reflow-Medical-Announces-12-Month-Results-from-DEEPER-REVEAL-Trial-Sustained-Outcomes-with-the-Spur-Stent-System-in-CLTI
2) Abbott: CE mark for the 76 mm Esprit BTK [Regulatory CE]
Line extension with no data of its own; the evidence remains LIFE-BTK with short lesions.
https://vascularnews.com/abbott-secures-ce-mark-for-longer-length-esprit-btk-system/
3) Shockwave becomes J&J MedTech as of October 1 [Industry]
Supplement on IVL in calcified CLTI: sponsored, with no new numerical data.
https://evtoday.com/news/shockwave-medical-to-rebrand-as-johnson-johnson-medtech
https://vascularnews.com/shockwave-ivl-the-first-line-strategy-for-calcified-clti-disease/
4) Clopidogrel metabolism variants and cardiovascular events after peripheral intervention (VAM 2026) [Congress]
~20% carriers; no increase in limb events, but more major adverse cardiovascular events (including myocardial infarction and stroke) over the following year. Observational, no effect-size figures; does not support routine genotyping.
https://vascularspecialistonline.com/study-links-clopidogrel-genetic-variants-to-cardiovascular-risk-after-pad-intervention/
Aorta
5) Endurant: CE mark without ruptured-AAA warning (Medtronic, Sep 3) [Regulatory CE]
Aligns Europe with the FDA (Oct 2025); ENGAGE registry at 10 years; no new rupture figures.
https://vascularnews.com/medtronics-endurant-stent-graft-system-receives-ce-mark-for-updated-rupture-labelling/
https://news.medtronic.com/Medtronic-Endurant-TM-stent-graft-system-first-and-only-to-receive-CE-mark-for-updated-rupture-labeling
Venous / PE
6) TRUST completes enrollment: Laguna in PE, n=107, 17 centers; results at VIVA October 5 [Clinical trial]
Single-arm, no data yet.
https://vascularnews.com/innova-vascular-announces-completion-of-enrollment-in-trust-trial-3/
https://classic.clinicaltrials.gov/ct2/show/NCT06041594
Hemodialysis access
7) aXess at 12 months: primary patency 34%, assisted 49%, cumulative 79% (n=120) [Publication-commentary]
Figures similar to ePTFE; data from the ongoing U.S. IDE trial are still pending.
https://vascularnews.com/european-axess-data-a-step-forward-in-an-evolving-field/
Technology
8) CE mark for the Photonova Spectra photon-counting CT (GE) [Regulatory CE]
According to the manufacturer, spectral imaging may help distinguish iodine, calcium and fat; no peripheral vascular studies.
https://vascularnews.com/ge-healthcare-lands-ce-mark-for-advanced-photon-counting-ct-system/
https://www.gehealthcare.com/en/about/newsroom/press-releases/ge-healthcare-s-photonova-spectra-gains-ce-mark-expanding-international-access
Meetings
CIRSE Copenhagen through Sep 9; Eastern Vascular Society, Washington, Sep 17–19; Midwestern Vascular, Chicago, Sep 17–20; NY Endovascular Summit, Sep 24–26; PE Symposium, Boston, Sep 30–Oct 3; VIVA, Las Vegas, Oct 4–7 (TRUST on the 5th); ESVS, Belgrade, Oct 6–9.
Note: this edition replaces the one sent at 11:24; an opinion item was removed and the DEEPER REVEAL figures were verified.
Kind regards.
Ready-to-paste LinkedIn post
Weekly vascular bulletin — September 7, 2026 A slow week for peripheral vascular clinical evidence, dominated by regulatory and industry news: 8 verified items covering Medicare reimbursement, CE marks and hemodialysis access. Three worth your time: • Medicare approves NTAP reimbursement (up to $2,596.75/case) for the Spur recoverable stent, based on single-arm DEEPER REVEAL data with no comparator. • aXess for hemodialysis access at 12 months (n=120): primary patency 34%, assisted 49%, cumulative 79% — figures similar to ePTFE, with U.S. IDE data still pending. • A VAM 2026 study links clopidogrel metabolism variants to more major adverse cardiovascular events (including MI and stroke) after peripheral intervention, though it does not support routine genotyping. Full bulletin: https://boletinesmedicos.com/en/vascular/2026-09-07.html
Ready-to-paste X (Twitter) post
Weekly vascular bulletin, Sep 7: Medicare approves NTAP for the Spur recoverable stent (DEEPER REVEAL data, no comparator); aXess at 12 months: primary patency 34%, cumulative 79% (n=120); clopidogrel variants linked to more major cardiovascular events post-PAD intervention. Full bulletin: https://boletinesmedicos.com/en/vascular/2026-09-07.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.